Area of research
Nephrology · Hematology
Research interest
Research interests include Medicine, Nephropathy, Internal medicine, Kidney disease, Proteinuria, and Placebo.
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
Fungal Planet description sheets: 1781‐1866
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial
WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy
Atrasentan in Patients with IgA Nephropathy
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort
Efficacy and Safety of Ravulizumab in IgA Nephropathy
IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy
An Update on Current Therapeutic Options in IgA Nephropathy
Targeting APRIL in the treatment of glomerular diseases
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort
WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
IgA nephropathy: the lectin pathway and implications for targeted therapy
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
Targeting the Endothelin A Receptor in IgA Nephropathy
Performance and limitations of a supervised deep learning approach for the histopathological Oxford Classification of glomeruli with IgA nephropathy
Clinical Characteristics and Outcomes of Drug-Induced Acute Kidney Injury Cases
Challenges in IgA Nephropathy Management: An Era of Complement Inhibition